Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial by Scurr, Martin et al.
Effect ofModified Vaccinia Ankara–5T4 and Low-Dose
Cyclophosphamide on Antitumor Immunity
inMetastatic Colorectal Cancer
A Randomized Clinical Trial
Martin Scurr, PhD; Tom Pembroke, PhD, MD; Anja Bloom, PhD; David Roberts, MD; Amanda Thomson, BSc; Kathryn Smart, BSc; Hayley Bridgeman, BSc;
Richard Adams, MD; Alison Brewster, MD; Robert Jones, MD; Sarah Gwynne, MD; Daniel Blount, PhD; Richard Harrop, PhD; MelissaWright, MSc;
Robert Hills, PhD; Awen Gallimore, DPhil; Andrew Godkin, MD
IMPORTANCE The success of immunotherapy with checkpoint inhibitors is not replicated in
most cases of colorectal cancer; therefore, different strategies are urgently required. The
oncofetal antigen 5T4 is expressed in more than 90% of cases of metastatic colorectal cancer
(mCRC). Preliminary data using modified vaccinia Ankara–5T4 (MVA-5T4) in mCRC
demonstrated that it safely induced serologic and T-cell responses.
OBJECTIVE To determine whether antitumor immunity in mCRC could be increased using
MVA-5T4, metronomic low-dose cyclophosphamide, or a combination of both treatments.
DESIGN, SETTING, AND PARTICIPANTS In this randomized clinical trial, 55 patientswith
inoperablemCRC and prior stable disease after standard chemotherapywere enrolled at a single
center and randomized towatch andwait (n = 9), cyclophosphamide treatment only (n = 9),
MVA-5T4 only (n = 19), and a combination ofMVA-5T4 and cyclophosphamide (n = 18). Patients
were enrolled and treated from July 9, 2012, through February 8, 2016, and follow-upwas
completed onDecember 13, 2016. Datawere analyzed based on intention to treat.
INTERVENTIONS Patients randomized to a cyclophosphamide group received 50mg twice
daily on treatment days 1 to 7 and 15 to 21. Patients randomized to a MVA-5T4 group received
an intramuscular injection at a dose of 1 × 109 50% tissue culture infectious dose on
treatment days 22, 36, 50, 64, 78, and 106.
MAIN OUTCOMES ANDMEASURES The predefined primary end point was themagnitude of
anti-5T4 immune responses (5T4-specific T-cell and antibody levels) generated at treatment
week 7. Secondary end points included analysis of the kinetics of anti-5T4 responses,
progression-free survival (PFS), and overall survival (OS).
RESULTS Fifty-twopatients (38menand 14women;mean [SD] age, 64.2 [10.1] years)were
included in the study analysis. The5T4-specific antibody immune responseswere significantly
increasedintheMVA-5T4(83.41[36.09]relativeunits[RU];P = .02)andcombinationtreatment(65.81
[16.68]RU;P = .002) groups comparedwith no treatment (20.09 [7.20]RU). Cyclophosphamide
depleted regulatoryT cells in 24of 27patients receivingMVA-5T4, independently prolonging
PFS (5.0vs2.5months; hazard ratio [HR],0.48;95%CI,0.21-1.11;P = .09).MVA-5T4doubled
baseline anti-5T4 responses in 16of 35patients, resulting in significantly prolongedPFS (5.6 vs
2.4months;HR,0.21;95%CI,0.09-0.47;P < .001)andOS(20.0vs10.3months;HR,0.32;95%CI,
0.14-0.74;P = .008).Nograde3or4adverse eventswereobserved.
CONCLUSIONSANDRELEVANCE This initial randomizedclinical immunotherapystudydemonstrates
asignificantsurvivalbenefit inmCRC.Priordepletionof regulatoryTcellsbycyclophosphamidedid
not increase immune responsesgeneratedbyMVA-5T4vaccination; however, cyclophosphamide
andMVA-5T4each independently inducedbeneficial antitumor immune responses, resulting in
prolongedsurvivalwithouttoxiceffects.Largerclinicaltrialsareplannedtofurthervalidatethesedata.
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C olorectal cancer (CRC) is the second leading cause ofdeath from cancer.1 Although early stages are oftencured by surgical resection, the prognosis for patients
withmetastatic colorectal cancer (mCRC) is very poor, with a
5-year survival rate of 7%.2
An unmet need for improved therapies exists; although
immunotherapy has been at the forefront of recent
advances, results in CRC have been disappointing. More
than 96% of patients with mCRC have microsatellite stable
tumors3 that do not respond to current immunotherapies,
possibly owing to decreased incidence of neoantigens.4-6
We hypothesized that in these patients, a well-targeted
immune response against an up-regulated tumor antigen
with minimal expression on healthy background tissues
represents a potentially more effective therapy. One candi-
date is 5T4, a trophoblast glycoprotein with restricted
expression to several human adenocarcinomas, including
more than 90% of CRCs.7,8 Previous studies9,10 demon-
strated that 5T4-specific interferon-γ–positive (IFN-γ+)
T-cell responses correlate with tumor stage, providing pro-
tection against metastasis.
Herein, we sought to improve 5T4 immune responses in
patients with mCRC through vaccination with an immuno-
genic, nonreplicating modified vaccinia Ankara–5T4 (MVA-
5T4; TroVax; Oxford BioMedica, plc). This vaccine has dem-
onstrated efficacy in preclinical models of colon cancer via
the induction of humoral anti-5T4 responses.11 Early indica-
tions in mCRC demonstrated an excellent safety profile,
with the induction of anti-5T4 responses correlating with
disease control, thus warranting further studies in random-
ized clinical trials.12
Previous attempts at vaccination strategies targeting
up-regulated tumor antigens have been largely unsuccessful
for many tumor types; however, a recent trial of MVA-5T4
encoding mucin 1 in advanced non–small cell lung cancer
demonstrated improvement in progression-free survival
(PFS).13 Such vaccines work by inducing the intracellular
expression of their respective transgene, allowing the tumor
antigen to be processed by major histocompatibility com-
plex classes I and II pathways. Given that activation of the
adaptive immune response may concurrently stimulate
tumor-specific regulatory T (Treg) cells, we also sought to
test the hypothesis that the effectiveness of cancer vaccines
is improved by prior administration of a Treg-depleting
agent. In low doses, cyclophosphamide has demonstrated
numerous immune-potentiating effects, including the
depletion and reduced functionality of Tregs.14,15 However,
to date, low-dose metronomic cyclophosphamide treatment
has not been evaluated in a randomized clinical setting for
cancer.
The trial reported herein is a randomized phase 1 and 2
clinical trial in patients with inoperable mCRC that assessed
the effectiveness of cyclophosphamide in increasing the
immunotherapeutic potential of MVA-5T4. We present
the final analyses of primary and secondary end points,
including an assessment of how anti-5T4 immune
responses and Treg cell depletion are associated with
patient survival.
Methods
Study Design and Participants
This open-label study was performed in a single center in the
Clinical Research Facility, University Hospital of Wales, Car-
diff. A copy of the trial protocol is found in Supplement 1. The
GeneTherapyAdvisoryCommitteeandtheCardiffandValeUni-
versityHealthBoardethicscommitteeapprovedthestudy.Trial
authorizationwas granted from theMedicines andHealthcare
ProductsRegulatoryAuthority.This trialwasconducted incom-
pliance with International Conference on Harmonisation and
GoodClinicalPracticeregulatoryrequirements.Allpatientsgave
written, informed consent before trial inclusion.
Patients underwent evaluation for recruitment at Velin-
dreNationalHealth ServiceTrust, Cardiff, and theSouthWest
Wales Cancer Centre, Singleton Hospital, Swansea. Patients
were eligible if they had inoperable stage IV CRC and evi-
dence of responding or stable disease within 4 weeks before
trial entry. Previous findings16 indicate that patients receiv-
ing palliative chemotherapy can safely be given protracted
breaks from chemotherapy with no evidence of a worsening
of their outcome. However, patients with elevated platelet
counts (>400000/μL [to convert to /×109/L,multiply by 1.0])
did not tolerate chemotherapy-free intervals and were ex-
cluded from this study. Additional exclusion criteria in-
cludedhemoglobin levels less than 11 g/dL (to convert tograms
per liter, multiply by 10.0), monocyte count greater than
80000/μL (to convert to /×109/L,multiply by0.001), comple-
tionof first-line chemotherapywithin2weeksbefore the start
of treatment, clinically apparent autoimmune disease, or use
of immunosuppressants.Key inclusioncriteria includedWorld
Health Organization performance status of 0 to 2, lympho-
cyte count of at least 500/μL (to convert to /×109/L, multiply
by 0.001), and neutrophil count of greater than 1200/μL
(to convert to /×109/L, multiply by 0.001).
Randomization andMasking
The trial was based on a 2 × 2 factorial design. Patients were
randomized 1:1 between receivingcyclophosphamideandnot,
Key Points
Question Does low-dose cyclophosphamide, modified vaccinia
Ankara–5T4, or a combination enhance antitumor immunity in
patients with metastatic colorectal cancer?
Findings In this randomized clinical trial of 55 patients, all 3
treatment regimens improved antitumor immunologic responses,
prolonging survival with no safety concerns. The addition of
cyclophosphamide did not affect the number of patients who
responded tomodified vaccinia Ankara–5T4; however, survival
outcomes improved in patients with metastatic colorectal cancer
who received low-dose cyclophosphamide treatment.
Meaning These data support the importance of well-targeted
antitumor immune responses, show the safety and antitumor
activity of low-dose cyclophosphamide andmodified vaccinia
Ankara–5T4, and support further investigation in metastatic
colorectal cancer.
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and 2:1 between receiving MVA-5T4 and not, resulting in the
following 4 treatment arms: control, or watch and wait (un-
less clinically indicated; group 1),metronomic cyclophospha-
mide only (group 2), MVA-5T4 only (group 3), or cyclophos-
phamideandMVA-5T4(group4) (Figure1).Randomizationwas
undertaken at theClinical TrialsOffice, UniversityHospital of
Wales, using an unstratified balanced block design, with the
outcome communicated to the attending physician immedi-
ately after randomization and participant enrollment. Treat-
ment allocation was not masked in this open-label study.
Procedures
Cyclophosphamide (Pharmacia Ltd) was orally administered
in doses of 50 mg twice per day on treatment days 1 to 7 and
15 to 21 or until the patient experienced relapse. Groups 2 and
4patientswere contactedby telephoneduring cyclophospha-
mide treatment to ensure compliance. MVA-5T4 was admin-
istered in an intramuscular injection at a dose of 1 × 109 50%
tissue culture infectious dose (TCID50) on treatment days 22,
36, 50, 64, 78, and 106. Peripheral blood samples were ob-
tained at regular intervals (Figure 2).
We performed physical examinations and full blood cell
counts,measurement of urea and electrolyte levels, and liver
function tests at each blood sample obtainment. Tumor bur-
denwasassessedquantitativelyusingResponseEvaluationCri-
teria in Solid Tumors (RECIST) criteria after computed tomo-
graphic scansof theabdomenandchestduring treatmentweek
12. Beyond 16 weeks of treatment, assessments were per-
formed every 12 weeks until documented disease progres-
sion,whereby thepatientwouldbe treatedwith standard che-
motherapy as indicated.
To assess immunologic responses, peripheral blood
mononuclear cells were isolated from heparinized blood
samples by centrifugation over density gradient media (Fi-
coll; GE Healthcare) and cultured in triplicate with 5T4 pep-
tide pools or control antigens for 14 days. We performed
IFN-γ enzyme-linked immunospot assays to assess for 5T4-
specific T-cell responses, as previously described.10 Positive
responses were identified as having at least 20 spot-forming
cells per 105 cultured peripheral blood mononuclear cells
and double the number of spots compared with back-
ground.
Figure 1. CONSORT FlowDiagram of Study Enrollment
55 Patients with mCRC underwent
assessment for eligibility
18 Discontinued
treatment due to
disease progression
55 Randomized
9 Randomized to group 1
(watch and wait)
8 Included in
intention-to-treat
analysis
9 Included in
intention-to-treat
analysis
17 Included in
intention-to-treat
analysis
18 Included in
intention-to-treat
analysis
9 Randomized to group 2
(cyclophosphamide only)
19 Randomized to group 3
(MVA-5T4 only)
18 Randomized to group 4
(cyclophosphamide
and MVA-5T4)
1 Excluded
(misdiagnosis)
1 Withdrew consent
after 1 day
(censored)
17 Discontinued
treatment due to
disease progression
1 Excluded
(misdiagnosis)
8 Discontinued
treatment due to
disease progression
1 Received surgery
(censored on date
of metastasectomy)
7 Discontinued
treatment due to
disease progression
mCRC indicates metastatic colorectal
cancer; MVA-5T4, modified vaccinia
Ankara–5T4 (TroVax; Oxford
Biomedica, plc).
Figure 2. Trial Treatment Schedule
Watch and wait 
Group 1
Treatment Day
Cyclophosphamide only
Group 2
MVA-5T4 only
Group 3
Cyclophosphamide and MVA-5T4
Group 4 
1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106
Cyclophosphamide was given in a dose of 50mg twice daily at treatment days 1
to 7 (week 1) and 15 to 21 (week 3) to groups 2 and 4 (shaded blocks). The
modified vaccinia Ankara–5T4 (MVA-5T4; TroVax; Oxford Biomedica, plc) was
given as an intramuscular injection in a dose of 1 × 109 50% tissue infectious
dose at treatment days 22 (week 4), 36 (week 6), 50 (week 8), 64 (week 10),
78 (week 12), and 106 (week 16) to groups 3 and 4 (injection graphic). Arrows
indicate days when blood samples were obtained.
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To perform T-cell counts, 3 μL of CD3-APC, CD4-PE, and
CD8-PerCPCy5.5 were added to 50 μL of whole heparinized
bloodusinga reversepipetting technique.Redbloodcellswere
lysedbeforeadditionof50μLabsolute countingbeads (Count-
Bright; ThermoFisher); samples were acquired on a cell ana-
lyzer (FACSCanto II; BDBiosciences), and cell countswere cal-
culated according to the manufacturer’s instructions. To
calculate theproportionofCD4+Tcells expressingFoxp3, fresh
peripheral blood mononuclear cells were stained with a fix-
able aqua dead cell stain kit (Live/Dead; Thermo Fisher Sci-
entific) and thenwithCD4-APCh7, followedby fixationand/or
permeabilization and intracellular staining with Foxp3-APC.
Plasma sampleswere collected fromblood samples sepa-
rated over the density gradient media to measure 5T4-
specific antibody level, determinedusing semiquantitativeen-
zyme-linked immunosorbentassaysaspreviouslydescribed.17
Polyclonalplasmapositive for5T4wasusedasastandardcurve
for each assay. A 2-fold increase in 5T4 antibody relative units
wasestablishedas the level atwhicha false-positive rateof less
than 1% could be expected, and antibody levels were consid-
ered to be positive above this value.
Outcomes
Giventhetrial’sprimaryobjective tomeasure theeffectofMVA-
5T4 and/or cyclophosphamide on antitumor immune re-
sponses, the primary end point was the magnitude of 5T4-
specific responsesat treatmentday43 (week7). Secondaryend
points includedthekineticsofanti-5T4 immuneresponsesover
time, PFS, overall survival (OS), treatment-emergent adverse
events, andTregcelldepletionduringcyclophosphamidetreat-
ment. We defined PFS as the time from the date of trial ran-
domization to the date of first documented tumor progres-
sion, as determined by evidence of radiologic progression on
computed tomographic scan or clinical deterioration as as-
sessed by the oncologist. We defined OS as the time from the
date of trial randomization to the date of death due to any
cause.
To assess safety, we reported adverse event occurrences
to the Data Monitoring and Ethics Committee after comple-
tion of treatment in every 6 patients in group 4. Safety in this
group was assessed weekly for the first 4 weeks.
Statistical Analysis
Follow-upwas completed onDecember 13, 2016, bywhich all
patients had experienced progression or received other treat-
ments. Powerwas based on themean effect size expected for
each treatment, allowing for possible synergy between the 2
treatments.A randomizationof 27vs 27patients to receive cy-
clophosphamide or not gave 80%power to detect amoderate
difference of 0.8 SD in antitumor immune response or other
laboratorymarkers. ForMVA-5T4 randomization, a total of 54
patients (allocated as 36vs 18) gave80%power todetect a dif-
ference of 0.83 points betweenMVA-5T4 or not. Because the
possible synergy between cyclophosphamide and MVA-5T4
was of interest, the MVA-5T4 randomization was in a ratio of
2:1; if such synergywas observed, a comparison of adding cy-
clophosphamide with MVA-5T4 would contain 36 patients,
enough for a difference of 1.0 SD with 80% power.
All analyses were performed on an intention-to-treat ba-
sis, with patients ineligible for the trial excluded. Wilcoxon
matched-pairs signed rank tests were used to compare non-
parametric data sets, including the assessment of Treg cell
depletion during cyclophosphamide treatment and 5T4 im-
mune responses generated; patients were subdivided based
on these results, according to endpoints stipulated in the trial
protocol.WeanalyzedOSandPFSusing log-rank tests anddis-
playedusingKaplan-Meierplots.Categorical data analysiswas
performedusing stratifiedMantel-Haenszel tests. Effect sizes
aredisplayedasPetoodds ratioswith95%CIs.Analysesofeach
treatment were performed stratified for the other treatment
allocationwithinthefactorialdesign,andstratifiedresultswere
displayed as forest plots. P < .05 was considered to be statis-
tically significant, and all tests of significance were 2 sided.
Analyses were performed using SAS (version 9.4; SAS Insti-
tute, Inc) and GraphPad Prism (version 7; GraphPad Soft-
ware, Inc) software.
Results
FromJuly9, 2012, throughFebruary8, 2016, 54patientswere
recruited and randomized. One patient from group 3 with-
drewconsent before receiving the allocated intervention, and
1patient each fromgroups 1 and3were later found tohaveun-
dergone a curative procedure before enrollment (Figure 1).
These 3 patients were not included in the analyses of im-
mune responses, PFS, andOS; however, an additional patient
was recruited to group 3 and was included in the analyses.
Thus, 52 patients were eligible for evaluation (38men and 14
women; mean [SD] age, 64.2 [10.1] years). The baseline char-
acteristicsof thepatients randomizedtothe4groupsareshown
in eTable 1 in Supplement 2. All patients presentedwith liver,
lung, and/or peritoneal metastases.
The key objectives of the studywere to determine the ef-
fect of low-dose cyclophosphamideonantitumor immune re-
sponses andwhether such treatment could enhance immune
responses generatedbyMVA-5T4vaccination.Cyclophospha-
mide alone induced many immunologic perturbations, most
evident being an increase in IFN-γ+ 5T4-specific T-cell re-
sponses and the depletion of Foxp3+ Treg cells (24 of 27 pa-
tients in groups 2 and 4) (Figure 3A); significant depletions in
Treg cells were noted during treatment week 3 at days 15
(53.22/μL [5.08/μL]; P = .01) and 18 (49.63/μL [5.61/μL];
P = .003) compared with treatment day 1 (61.48/μL [5.28/
μL]) (Figure3B).Witha thresholdofadecrease inabsoluteTreg
cell numbers (ie, percentage of Treg cell depletion) set above
the upper 95% CI (Figure 3C), those patients exhibited pro-
longedmedian PFS comparedwith nonresponding (ie, below
the threshold) patients (5.0 vs 2.5months; hazard ratio [HR],
0.48; 95% CI, 0.21-1.11; P = .09) (Figure 3D) (data are shown
stratified byMVA-5T4 in eFigure 1 in Supplement 2). Thus, ef-
fective cyclophosphamide-induced Foxp3+ Treg cell deple-
tionwas associatedwithprolongedPFS, but statistical signifi-
cancewasnot reached likelyowingtosamplesizeandthestudy
not beingpowered todirectly address this. TheTreg cell num-
bers returnedtobaselinebytreatmentday29inpatients treated
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withcyclophosphamideonlyand remainedat this level for the
duration of the trial.
The presence of anti-5T4 immune responses was ana-
lyzed throughout the trial. Significant increases in 5T4 anti-
body level were evident after 2 vaccinations at treatment day
43 in group 3 (83.41 [36.09] relative units [RU]; P = .02) and
group4 (65.81 [16.68]RU;P = .002) (Figure4A)comparedwith
group1 (20.09 [7.20]RU); thus, theprimaryendpointwasmet.
After treatment day 43, 5T4 antibody levels increased further
for many patients, including at treatment day 78 in group 3
(153.6 [45.94] RU; P < .001) and group 4 (242.9 [76.69] RU;
P = .003), comparedwithgroup 1 (14.41 [3.36]RU) (Figure4A).
Despite group 4 exhibiting larger increases compared with
group 3 in anti-5T4 antibody titers (and corresponding anti-
MVA titers in eFigure 2 in Supplement 2) at treatmentdays64,
78, and 106, differences were not significant. Anti-MVA anti-
bodieswere detected at similar points, but only small nonsig-
nificant reductions were noted in 5T4 antibody levels after
treatment day 64.When analyzing secondary end points, de-
velopmentof 5T4antibodieswas consistent amongMVA-5T4-
treated patients, with 15 of 17 group 3 and 13 of 18 group 4 pa-
tients havingmore than a2-fold increase in anti-5T4antibody
levels at some time during the trial (Figure 4B). A single in-
stance was found of a cyclophosphamide-only treated pa-
tient also having a doubled anti-5T4 antibody response dur-
ing treatment (Figure 4B).
Themaximum increase in baseline 5T4-specific IFN-γ+T-
cell responses revealed varying degrees of T-cell response to
MVA-5T4vaccination,with20of 35patientshavingmore than
a 2-fold increase. Among groups 1 and 2, 10 of 17 patients had
more than a 2-fold increase, owing mostly to cyclophospha-
mide increasing anti-5T4 T-cell responses via Treg cell deple-
tion (Figure 4B).
Whenconsideringall trial participantswhohadmore than
a 2-fold increase in anti-5T4 T-cell and antibody responses to
cyclophosphamideorMVA-5T4at any instanceduring the trial
(Figure 4B), the increase was associated with prolonged PFS
(5.7 vs 2.4months;HR,0.58; 95%CI, 0.31-1.09;P = .09) (eFig-
ure3A inSupplement2) andOS (20.0vs 13.1months;HR,0.56;
95%CI,0.28-1.12;P = .10) (eFigure3B inSupplement2).Among
groups 3 and 4MVA-5T4–treated patients, this effect became
moreapparent because removinggroups 1 and2patients from
the analysis revealed a significant difference inPFS (5.6 vs 2.4
months;HR,0.21; 95%CI,0.09-0.47;P < .001) (Figure4C) and
OS (20.0vs 10.3months;HR,0.32;95%CI,0.14-0.74;P = .008)
(Figure4D).Large increases inMVAtiters toMVA-5T4werealso
Figure 3. Progression-Free Survival (PFS) in Response to Cyclophosphamide
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significantly associated with PFS (HR, 0.26; 95% CI, 0.11-
0.59; P = .001) (eFigure 2B andC in Supplement 2) but not OS
(HR, 0.69; 95% CI, 0.32-1.51; P = .36) (eFigure 2B and D in
Supplement 2); thus, general immunologic responsiveness of
the patient may also determine outcome.
Althoughbeneficial immunologic responses to cyclophos-
phamideorMVA-5T4were independentlyassociatedwithpro-
longed PFS compared with no treatment (group 1), neither
treatment was more effective than the other (eFigure 1 and
eFigure 4A andB in Supplement 2), nor did patients receiving
combination treatment in group 4 exhibit improved survival
comparedwithMVA-5T4–onlygroup3 (Figure5AandB).Seven
of 18 patients in group 4 had 5T4 T-cell and antibody re-
sponses at any point in the trial, but this was not statistically
different from the 9 of 17 patients in group 3 who had similar
responses to MVA-5T4 alone (P = .60) (eFigure 1A in
Supplement 2). Therefore, the addition of cyclophospha-
midedoesnotenhance theeffectivenessofMVA-5T4,nordoes
it appear to lessen response to vaccination.
All 3 treatmentgroupsdemonstrated improvedPFSbutnot
OScomparedwith thecontrol group (Figure5CandD);OSdata
aredifficult to interpret because subsequent interventions of-
fered to thesepatients is beyondour control. Patients in group
2 demonstrated the greatest increase in median PFS com-
pared with group 1 (HR, 0.32; 95% CI, 0.09-1.09; P = .07)
(Figure 5A), although the number of patients is small. There-
fore, in patients with mCRC, receiving treatment with MVA-
5T4 or low-dose cyclophosphamide was more effective than
allowing a protracted break from chemotherapy. In addition,
we found no instances of treatment-related grade 3 or 4 ad-
verse events (eTable 2 in Supplement 2), suggesting an excel-
lent safety profile of these interventions.
Figure 4. Anti-5T4 Immunologic Responses AssociatedWith Survival
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calculated compared with group 1. B, Fold increases in 5T4-specific
interferon-γ–positive (IFN-γ+) T-cell and antibody responses were calculated by
dividing the highest response to treatment at treatment days 8 through 106 by
baseline (treatment day 1) level. Shaded symbols indicate the 16 recipients of
themodified vaccinia Ankara–5T4 (TroVax; Oxford Biomedica, plc) (groups 3
and 4) demonstrating more than a 2-fold increase in anti-5T4 T-cell and
antibody responses at any treatment day (responders). C and D, These patients
exhibited significantly increased progression-free survival (PFS) (hazard ratio
[HR], 0.21; 95% CI, 0.09-0.47; P < .001) and overall survival (OS) (HR, 0.32;
95% CI, 0.14-0.74; P = .008) compared with less than a 2-fold response to
MVA-5T4 (nonresponders). Groups are described in Figure 1.
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Discussion
This randomized study demonstrated the clinical benefit of a
combined vaccine and low-dose cyclophosphamide in the
treatment of mCRC. Each treatment improved antitumor im-
munity throughdifferentmechanisms;cyclophosphamidewas
effective at depleting Foxp3+ Treg cells, resulting in in-
creasedanti-5T4T-cell responses,which isassociatedwithsur-
vival, andMVA-5T4was effective at inducing cellular andhu-
moral anti-5T4 responses, increasingPFSandOS ina subgroup
analysis of patients with and without a treatment response.
In combination, however, cyclophosphamide did not im-
prove anti-5T4 responses duringMVA-5T4 treatment despite
amodest increase in anti-5T4antibody level. This findingmay
reflect cyclophosphamideblocking thepriming andprolifera-
tion of other important immune cell subsets required for ef-
fective vaccination (eg, tumor antigen–specific effectorT cells
anddendritic cells).18,19 Future studieswill aimtodecipher the
exact effect ofmetronomic oral cyclophosphamideon immu-
nologic responsesandhowitmight impingeonothercellpopu-
lations.
Saito et al20 recently hypothesized that depletion of sup-
pression-competentTreg cells expressinghigh levels of Foxp3
andabundant inCRCmayprovideclinical benefit, andour trial
findings appear to corroborate their hypothesis. Several
studies21-23 have indicatedabetter prognosiswhen tumors are
infiltrated with relatively high numbers of Foxp3+ Treg cells.
Aprevious study10 demonstrated that as tumors advance, pe-
ripheral Treg cell proportion and suppressive capacity in-
crease; in addition, Treg cell depletion significantly improves
antitumor immune responses in mice24 and patients with
CRC.9,10,25 In the present trial, when Treg cells were most ef-
fectively depleted, median PFS doubled (from 2.5 to 5.0
Figure 5. Kaplan-Meier Survival Curves by Trial Group
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Outcomes for all patients by trial group are indicated for progression-free
survival (PFS) and overall survival (OS). Outcomes of 44 patients receiving any
treatment (groups 2, 3, and 4) vs 8 control individuals (group 1) are indicated
for PFS (HR, 0.41; 95% CI, 0.20-0.88; P = .02) and OS (HR, 1.03; 95% CI,
0.43-2.47; P = .95). Groups are described in Figure 1.
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months). Although our evidence is limited to depletion of pe-
ripherally derived Foxp3+ Treg cells, the increase in PFS indi-
cates effective tumor control through the probable concur-
rent depletion of intratumoral Treg cells, thus removing the
suppressionof intratumoral effectors.We find it plausible that
colorectal tumor–specificTregcells inadvanceddiseasearedet-
rimental to patients, andhigh preexisting Foxp3+ Treg cell in-
filtration is a bystander effect of a larger antitumor immune
response.26
Regardless of mechanism, anti-5T4 responses during cy-
clophosphamide treatment orMVA-5T4 vaccinationwere as-
sociatedwith a statistically significant increase inPFS andOS.
Similar to previous trials of MVA-5T4, in which intramuscu-
lar injection of 1 × 109 TCID50 of MVA-5T4 induced the stron-
gest immune response correlatingwithdisease control,17,27,28
the vaccine was shown to be safe and well tolerated, and the
induction of an anti-5T4 immune response did not result in
any detrimental off-target autoimmunity.
Prior chemotherapeutic regimens in this group of pa-
tients with mCRC appeared to have little effect on responses
to either immunotherapeutic treatment (eTable 1 in
Supplement 2), although some patients began the trial with
relatively highpreexisting anti-5T4 responses, potentially in-
ducedbyprior treatments.We foundno evidence of preexist-
ing responses correlatingwith improved outcomes, although
patients with higher preexisting 5T4 antibody levels exhib-
ited significantly higher 5T4 antibody responses toMVA-5T4
during treatment.
Large increases inTregcellsoccurred inseveralpatients re-
gardless of prior cyclophosphamide treatment, in particular
amongpatientswithanHLA-DR1+/DQ5+ responseafter a single
MVA-5T4 injection. Although this factor, alongwith increased
MVA antibody level (eFigure 2 in Supplement 2), initially sug-
gested the induction of peripheral tolerance toMVA-5T4, anti-
5T4 T-cell and antibody responses remained largely unaf-
fected. We also found no correlation between high anti-MVA
titers and lowanti-5T4 responses, althoughanassociationwas
identified between large increases in anti-MVA titers and PFS
but notOS (eFigure 2 in Supplement 2), indicating that general
patient health and immunocompetence may play a role in re-
sponsiveness to immunotherapy.GiventhatT-cell responses to
the control antigen tuberculin purified protein derivative var-
ied little during the trial and were not associated with patient
outcome (eFigure 5 in Supplement 2), the key immune re-
sponses may be those generated against tumor antigens (eg,
5T4).ThisevidencesupportsexploringtheuseofMVA-5T4(and
other cancer vaccines29) earlier in the disease course.
Limitations
Important limitations include the relatively small sample size,
in particularwhenanalyzingTreg cell depletion andperform-
ing survival analyses among group 2patients receiving cyclo-
phosphamide. These findings need to be validated in larger
clinical trials. In addition, the overall survival readouts pre-
sented herein are hindered by subsequent treatments the pa-
tients receive beyond our control.
Conclusions
This randomized clinical trial identified a subset of immuno-
therapy-responsive patients with mCRC who demonstrated
better tumor control when given cyclophosphamide orMVA-
5T4. Although cyclophosphamide failed to enhance MVA-
5T4 immunogenicity, survival benefitswithminimal adverse
effects were demonstrated, and further investigation is war-
ranted.Becauseof cyclophosphamide’s ineffectiveness in sus-
tained Treg cell depletion during MVA-5T4 vaccination, we
would propose the combination of MVA-5T4 with more po-
tent blockade of tumor-derived immunosuppression for fu-
ture development, for example with anti–CTLA-4 to elimi-
nate intratumoral Treg cells30 or with anti–LAG-3 checkpoint
inhibitors, given the extent of infiltration of highly suppres-
sive LAG-3+CD4+ tumor-infiltrating T cells.31
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